These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15015970)

  • 1. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.
    Chang H; Sloan S; Li D; Zhuang L; Yi QL; Chen CI; Reece D; Chun K; Keith Stewart A
    Br J Haematol; 2004 Apr; 125(1):64-8. PubMed ID: 15015970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
    Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
    Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
    Gutiérrez NC; Castellanos MV; Martín ML; Mateos MV; Hernández JM; Fernández M; Carrera D; Rosiñol L; Ribera JM; Ojanguren JM; Palomera L; Gardella S; Escoda L; Hernández-Boluda JC; Bello JL; de la Rubia J; Lahuerta JJ; San Miguel JF;
    Leukemia; 2007 Jan; 21(1):143-50. PubMed ID: 17024116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM; Abdelwahed E
    Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
    Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
    Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.
    Butler C; Wolff DJ; Kang Y; Stuart RK; Costa LJ
    Leuk Lymphoma; 2012 Dec; 53(12):2444-8. PubMed ID: 22574971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
    Pawlyn C; Melchor L; Murison A; Wardell CP; Brioli A; Boyle EM; Kaiser MF; Walker BA; Begum DB; Dahir NB; Proszek P; Gregory WM; Drayson MT; Jackson GH; Ross FM; Davies FE; Morgan GJ
    Blood; 2015 Jan; 125(5):831-40. PubMed ID: 25428216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
    Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis.
    Chang H; Li D; Zhuang L; Nie E; Bouman D; Stewart AK; Chun K
    Leuk Lymphoma; 2004 May; 45(5):965-9. PubMed ID: 15291356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
    Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
    Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
    Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
    Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
    Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE
    Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
    Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
    Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
    Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
    Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
    Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.
    Walters DK; Arendt BK; Tschumper RC; Wu X; Jelinek DF
    Exp Hematol; 2018 Jan; 57():42-49.e1. PubMed ID: 29030084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.
    Cook JR; Hartke M; Pettay J; Tubbs RR
    J Mol Diagn; 2006 Sep; 8(4):459-65. PubMed ID: 16931586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.